阿伯兰 候弗（ABRAM HOFFER）（生于1917年~）是 正分子医学的创始人之一，因在治疗精神分裂症和其它疾病中使用营养素和维生素疗法（主要是烟酸和维生素C）而闻名。
要了解更多有关阿伯兰 候弗以及他的医学学术，可访问以下网址：www.orthomed.org, http://www.answers.com/topic/abram-hoffer
阿伯兰 候弗（ABRAM HOFFER）
Vitamin B-3 and Schizophrenia.
作者: Abram Hoffer
候弗医生以烟酸治疗过的精神分裂症病人超过5000例, 他使用的正常剂量是每天3~6克, 而且他发现,烟酸对肝脏并没有明显的毒性作用。有关烟酸对肝脏的毒性作用的结论是在特殊背景下取得的，此后的教科书和出版物只是简介重复当初这个结论。。。译者
Vitamin B-3: Niacin and Its Amide
by A. Hoffer, M.D., Ph.D.
Niacin, Coronary Disease and Longevity
by Abram Hoffer, M.D., Ph.D.
Hoffer A. Niacin, Coronary Disease and Longevity. J Orthomolecular Medicine 4:211-220, 1989.
Clinical Procedures in Treating Terminally Ill Cancer Patients with Vitamin C
by Abram Hoffer, M.D., Ph.D
亚伯兰 候弗是加拿大一位德高望重的精神病医师,亦是正分子医学的创始人之一,加拿大和国际精神分裂症基金会的主席. 以善于运用维生素B-3和维生素C等营养素治疗精神分裂症而闻名。而维生素C和维生素B-3可以治疗癌症则是他在治疗因患上癌症而得精神病的病人时的偶然发现。本篇报告一定会为哪些患上癌症的人士以及他们的家属带来更多的希望。-译者
从精神分裂症的迷雾中出来Emerging From a Schizophrenic Haze
by Jack Challem and Renate Lewin
Abram Hoffer Autobiography
I was born on a farm in Southern Saskatchewan in 1917 in our first wooden house. My three older siblings were born in a sod shack. Public and high school education was completed in single room schools.
I combined my new interest in biochemistry with my original interest in agriculture by taking a Masters degree in agricultural chemistry in 1940 at the University of Saskatchewan in Saskatoon. On a graduate scholarship I studied for the following year at the St. Paul campus of the University of Minnesota, and then worked at a flour laboratory in Winnipeg developing chemical assay methods for thiamine in flour and other wheat products, and running the control analysis to ensure that the correct quantity of vitamins was added to the flour. I did my research toward my Ph.D. in this laboratory and received my degree in 1944.
By then I had become interested in human nutrition and enrolled in medicine at the University of Saskatchewan in 1945. For a few days before I finally registered I was shaken by an offer by Dr. T. Thorvaldson, Head Department of Chemistry, to accept a job as Professor of Agricultural Chemistry at a salary of $2700 per year. The salary was acceptable, but as my plans had already been made I maintained my resolution to take medicine.
I married Rose Miller in 1942. Bill was born in 1944. While I was interning in 1950 I was offered the position of Professor of Biochemistry at the same University. After two preclinical years at this university, and two clinical years at University of Toronto, I earned my M.D. in 1949. John was born in 1947 and Miriam in 1949.
Entering Psychiatric Research
I interned for one year at City Hospital in Saskatoon, planning on going into general practice, but hoping that I could eventually enter research. While interning I became interested in psychiatry, especially psychosomatic medicine. Toward the end of the year I applied for a position with Psychiatric Services Branch, Department of Public Health at Regina, Sask. I had discussed with the chief, Dr. D. G. McKerracher, my interest in combining my interests in medicine, chemistry and psychiatry in a research position. I joined him in July 1, 1951. I was given three missions: (1) to master psychiatry in preparation for qualifying for the specialty; I was fully qualified in 1954, and a few years later became a Fellow in the Royal College of Physicians and Surgeons (Canada). (2) To be consultant in biochemistry to the general hospital at Regina and, (3) to initiate a program of research into psychiatry.
January and February 1951, my wife and I toured the few research centers in psychiatry in Canada and the United States for six weeks. This proved very valuable when later we decided which research program we would start. The three most memorial visits were with Dr. Nolan D. C. Lewis, at the Psychiatric Institute in New York, Dr. H. Kluver, Culver Hall, University of Chicago, and Dr. Franz Alexander, at a psychoanalytic institute which he directed. Lewis and Kluver introduced me to the fascinating possibilities of the hallucinogens, especially mescaline, and from Dr. Alexander's luncheon clinic I learned that psychosomatic medicine had no basis in fact.
Dr. H. Osmond joined us in Saskatchewan in the fall of 1952. We soon were good friends and close colleagues. We organized and directed the research program until he left in 1960, and I went into private practice in 1967.
We decided to tackle the most important single problem, schizophrenia. Half of our mental hospital beds were occupied by these patients, and one quarter of all hospital beds in Canada were these patients. But there were very few tangible leads. Psychoanalysis was sweeping into North American psychiatry, and the biological psychiatrists were facing imminent defeat in their views about the nature of this disease.
Dr. Osmond and Dr. J. Smythies had discovered that the mescaline experience resembled the schizophrenic experience, and he and Smythies postulated that there might be a substance in the body with the properties of mescaline and related to adrenalin. Dr. Osmond and I developed this idea, which became known as the adrenochrome hypothesis of schizophrenia.
In 1954 we received a very large grant from the Rockefeller Foundation to continue this investigation. Before I could get the grant I was to travel to Europe and visit the research centers there. By the time I left research we had a very large well established research group, a truly cross-fertilized group in which psychologists, psychiatrists, nurses, and social workers all worked together.
Arising from this research are the following discoveries: (1) That adrenochrome is an hallucinogen, (2) that it could be made in the body. It is now known to be present and easily measured. (3) That megadoses of vitamin B-3 and ascorbic acid were therapeutic for schizophrenia. This was one of the roots of orthomolecular psychiatry and medicine as it is known today. (4) That niacin lowers cholesterol levels. This vitamin is now one of the world's standard materials for doing so. It also extends life and does not increase deaths from violent acts as some of the other compounds which lower cholesterol do. (5) The HOD (Hoffer-Osmond Diagnostic) and EWI tests for assisting in the diagnosis of schizophrenia. This is an excellent test, hardly known to the profession.
In pursuing this research we were the first psychiatrists in America to conduct double blind controlled tests, and we were later the first to recognize and to publish its many defects and flaws. Our discovery that niacin lowers cholesterol, published in 1955, is credited with the initiation of the new paradigm in nutritional medicine, i.e. the use of vitamins for treatment and not just for prevention of deficiency disease.
I gave up my two positions, Associate Professor of Psychiatry and Director of Psychiatric Research, because my freedom to publish and discuss our therapeutic trials using vitamins was being severely restricted by my two main employers, the University of Saskatchewan and the Department of Public Health. The psychiatric establishment was violently opposed to our work, which did not have the support of the drug companies who were promoting their own products, the tranquilizers. Not a single attempt was made to repeat our double blind controlled studies (five), nor to examine our claims clinically. I decided I could be more effective free of any of these adverse influences.
Since then I have been happily working with thousands of patients, applying what we had discovered in those early years in Saskatchewan. I have published many hundreds of reports in the medical and psychiatric literature, but after our views became widely known the establishment literature would no longer accept any and our reports went to the alternative literature instead. I have authored many books.
I have been active in the International Schizophrenia Foundation, now (2006) in its 38th year, and was one of the organizers of the former Huxley Institute of Biosocial Research. I am editor of the Journal of Orthomolecular Medicine, http://orthomolecular.org/library/jom/index.shtml and http://www.orthomed.org/jom/jom.html
which was the first medical journal to bring attention to many important new treatments in medicine such as the yeast syndrome, the toxicity of mercury from amalgams, the orthomolecular treatment of the schizophrenias and many other conditions.
My main interest since 1967 in Saskatoon, and in Victoria, B.C., after 1976, has been to promote the principles of orthomolecular medicine and psychiatry. In medicine the move into nutrition or orthomolecular medicine is well underway, and will sweep into most of the medical schools within the next five years. The move into psychiatry has been dismally slow. Psychiatrists can not untrack themselves from the influence of the tranquilizers, which are helpful, but when used alone hardly ever restore a schizophrenic patient to normal. My definition of a normal person is one who is free of signs and symptoms, gets on well with family, gets on well with the community, and pays income tax. Up to 90% of early patients, not yet badly damaged by the illness and the way it was treated, will achieve this. With chronic patients most will achieve this after 6 or 7 years of treatment. The treatment has been described many times. Literature is available from the International Schizophrenia Foundation, 16 Florence Avenue, Toronto, Canada M2N 1E9, telephone number (416) 733-2117, fax number (416) 733-2352.
I am pleased with my medical colleagues who are quickly moving into this modern paradigm, and am very frustrated by the massive inertia of my psychiatric colleagues who are still waiting for the Holy Grail, that new tranquilizer which appears every year, which will do for schizophrenia what insulin does for diabetes. The number of homeless chronic schizophrenics in the streets of all large American and Canadian cities is evidence of their inability to do more them than we could do in 1950 before we had any tranquilizers. But at least then we had hospitals which provided shelter and food and some care. Today the downtown slums have become the surrogate mental hospital beds for the chronic patients whose treatment has been wholly tranquilizers.
About thirty years ago I predicted that it would take at least forty years before megavitamin treatment would be accepted. After all, Moses walked his Israelite followers in circles in the desert for 40 years before initiating the invasion of the Holy Land. He realized that two generations of people born and raised in slavery would have to die before he could depend upon them to have enough fighting spirit and spunk to attempt the invasion. Do we have to wait for more than two generations of psychiatrists bred in the analytic and tranquilizer era to die before their offspring can begin to think about orthomolecular treatment of schizophrenic patients? Our first megavitamin treatment paper was published in 1957.
(For more information, you may wish to read Dr. Hoffer’s complete scientific memoirs, available at http://www.orthomed.org/store/store.html )
Reprinted with permission of the author.